About Urovant Sciences Ltd.

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -3.43$ per share.

The book value per share is 0.78$

Urovant Sciences Ltd. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -108M - -110M -3.43 - - 30M 0.78 -112M -1M -113M